Ginkgo Bioworks Holdings Stock Performance
| DNA Stock | USD 8.87 0.17 1.95% |
The company retains a Market Volatility (i.e., Beta) of 2.47, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ginkgo Bioworks will likely underperform. At this point, Ginkgo Bioworks Holdings has a negative expected return of -0.83%. Please make sure to check out Ginkgo Bioworks' maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Ginkgo Bioworks Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Ginkgo Bioworks Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.95 | Five Day Return 4.72 | Year To Date Return 1.95 | Ten Year Return (97.81) | All Time Return (97.81) |
Last Split Factor 1:40 | Last Split Date 2024-08-20 |
1 | DJI ROMO, il primo robot aspirapolvere con il DNA e la tecnologia dei droni atterra nella tua casa | 10/28/2025 |
2 | Bodies of infants found at mother and baby home | 11/07/2025 |
3 | Disposition of 1061 shares by Mark Dmytruk of Ginkgo Bioworks subject to Rule 16b-3 | 11/28/2025 |
4 | Disposition of 1244 shares by Mark Dmytruk of Ginkgo Bioworks at 7.283 subject to Rule 16b-3 | 12/01/2025 |
5 | Atlas Data Storage Introduces the Worlds First Scalable DNA Data Storage Offering | 12/02/2025 |
6 | Ginkgo Bioworks Shares Gap Up Whats Next | 12/05/2025 |
7 | DNASTONE CELEBRATES YEAR OF TRANSFORMATION, CREATIVE MOMENTUM, INDUSTRY RECOGNITION AND STRATEGIC TALENT GROWTH | 12/11/2025 |
8 | Disposition of 312 shares by Coen Steven P. of Ginkgo Bioworks subject to Rule 16b-3 | 12/12/2025 |
9 | DNA My Dog Releases Annual List of 2025s Most Popular Dog Names | 12/16/2025 |
10 | I was abandoned as a baby 81 years ago. Ive lived a mile from my brother all this time | 12/19/2025 |
11 | Ginkgo Bioworks Trading 10 percent Higher Heres What Happened | 12/22/2025 |
12 | Ginkgo Bioworks Holdings, Inc. Rises As Market Takes a Dip Key Facts | 12/31/2025 |
| Begin Period Cash Flow | 989.6 M | |
| Total Cashflows From Investing Activities | -62.2 M |
Ginkgo Bioworks Relative Risk vs. Return Landscape
If you would invest 1,609 in Ginkgo Bioworks Holdings on October 8, 2025 and sell it today you would lose (722.00) from holding Ginkgo Bioworks Holdings or give up 44.87% of portfolio value over 90 days. Ginkgo Bioworks Holdings is generating negative expected returns assuming volatility of 5.2459% on return distribution over 90 days investment horizon. In other words, 47% of stocks are less volatile than Ginkgo, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Ginkgo Bioworks Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ginkgo Bioworks' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ginkgo Bioworks Holdings, and traders can use it to determine the average amount a Ginkgo Bioworks' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1583
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DNA |
Based on monthly moving average Ginkgo Bioworks is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ginkgo Bioworks by adding Ginkgo Bioworks to a well-diversified portfolio.
Ginkgo Bioworks Fundamentals Growth
Ginkgo Stock prices reflect investors' perceptions of the future prospects and financial health of Ginkgo Bioworks, and Ginkgo Bioworks fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ginkgo Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.88) % | ||||
| Operating Margin | (2.27) % | ||||
| Current Valuation | 488.14 M | ||||
| Shares Outstanding | 48.52 M | ||||
| Price To Earning | 25.51 X | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 2.92 X | ||||
| Revenue | 227.04 M | ||||
| Gross Profit | 131.31 M | ||||
| EBITDA | (484.39 M) | ||||
| Net Income | (547.03 M) | ||||
| Cash And Equivalents | 561.57 M | ||||
| Cash Per Share | 0.84 X | ||||
| Total Debt | 467.73 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | 9.85 X | ||||
| Cash Flow From Operations | (319.58 M) | ||||
| Earnings Per Share | (6.18) X | ||||
| Market Capitalization | 527.13 M | ||||
| Total Asset | 1.38 B | ||||
| Retained Earnings | (5.84 B) | ||||
| Working Capital | 495.48 M | ||||
| Current Asset | 10.07 B | ||||
| Current Liabilities | 3.1 B | ||||
About Ginkgo Bioworks Performance
By analyzing Ginkgo Bioworks' fundamental ratios, stakeholders can gain valuable insights into Ginkgo Bioworks' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ginkgo Bioworks has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ginkgo Bioworks has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.36 | 0.34 | |
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.88) | (0.92) |
Things to note about Ginkgo Bioworks Holdings performance evaluation
Checking the ongoing alerts about Ginkgo Bioworks for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ginkgo Bioworks Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ginkgo Bioworks generated a negative expected return over the last 90 days | |
| Ginkgo Bioworks has high historical volatility and very poor performance | |
| Ginkgo Bioworks has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 227.04 M. Reported Net Loss for the year was (547.03 M) with profit before taxes, overhead, and interest of 131.31 M. | |
| Ginkgo Bioworks Holdings has about 561.57 M in cash with (319.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Ginkgo Bioworks has a poor financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Ginkgo Bioworks Holdings, Inc. Rises As Market Takes a Dip Key Facts |
- Analyzing Ginkgo Bioworks' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ginkgo Bioworks' stock is overvalued or undervalued compared to its peers.
- Examining Ginkgo Bioworks' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ginkgo Bioworks' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ginkgo Bioworks' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ginkgo Bioworks' stock. These opinions can provide insight into Ginkgo Bioworks' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ginkgo Stock analysis
When running Ginkgo Bioworks' price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |